Core Insights - KOORUI launched its G Series gaming monitors, G2411P and G2741L, designed for mainstream gamers and creative professionals, emphasizing precision, speed, and compatibility [1][2] - The G Series monitors achieved significant market success on Prime Day, with G2411P entering the Top 10 best-selling monitors on Amazon US and showing increased search volume and conversion rates [2][6] - KOORUI's strategy focuses on enhancing user experience rather than just specifications, aiming to make high-performance gaming accessible to a broader audience [3][6] Company Overview - KOORUI was founded with the belief that intelligent technology should enhance everyday life, with a team dedicated to making smart, high-quality products affordable [4][7] - The product lineup includes a range of monitors from entry-level 75Hz to high-end 200Hz+ displays, featuring various panel types and eco-conscious designs [5][6] - KOORUI is increasingly recognized as a smart, experience-first choice for gamers and professionals, moving beyond its initial entry-level positioning [6]

Core Insights - Defence Therapeutics Inc. is advancing its ADC and Radiopharma programs, focusing on collaborations and preclinical studies for cancer therapies using its Accum® technology [1][2][3] ADC Program - Defence's Accum®-based ADCs show improved intracellular delivery and cytotoxic activity in various preclinical cancer models compared to traditional ADCs [2] - The company is optimizing additional Accum®-based ADCs to enhance their value and attract potential licensing and co-development opportunities with Pharmaceuticals and Biotech companies [2] Radiopharmaceutical Program - The Radiopharma program is enhancing Accum® radiolabelling through studies conducted by Canadian Nuclear Laboratories, focusing on biodistribution, pharmacokinetics, and therapeutic potency [3] - The application of Accum® technology in the radiopharmaceuticals sector is expected to be transformative [3] Market Outlook - The global ADC market is projected to grow from USD 13.51 billion in 2025 to USD 29.9 billion by 2034, with a CAGR of 9.23% from 2024 to 2034 [4] - The global radiopharmaceutical market is expected to reach USD 16.87 billion by 2033, growing at a CAGR of 9.9% during 2025-2033 [4] Future Developments - The company plans to announce key results and partnership details as they become available, while continuing its studies in Canada and expanding its presence to the US [5] - Defence Therapeutics is a clinical-stage biotechnology company focused on developing next-generation ADC products using its proprietary Accum® technology [6]

and CardanoStellar up 99%amazing technology ...

The digital economy as we know it was born out of post Cold-War optimism and globalization. Liberal democracy would continue to spread. Governments and companies were accustomed to global market access and frictionless trade. The likes of Google and Facebook were born out of the belief that borderless innovation and limited interference by governments were preordained. But rather than a new normal of uninterrupted globalization destined to continue forever, the book argues that this period of globalization ...

11 July 2025 | 12:20AM HKT AMEC (688012.SS): Mgmt. call: Solid order from memory and logic; accelerated R&D cycle on new products; Buy We hosted AMEC management on July 10 in our China Semis Corp Call series (July 7 - 10). Key discussions focused on order momentum, China semis capex outlook, and product expansion plans. Overall, management maintained their positive tone of solid order growth driven by clients' capacity expansion and the increasing penetration of domestic equipment. The company is actively e ...

A ferocious advance in Chinese biotech is challenging Western dominance in drug innovation https://t.co/VmMLoJLBVj ...

A former voting tech auditor claims that voting machines still lack key security fixes flagged in 2006, leaving U.S. elections vulnerable. https://t.co/2POrSofmAS ...

The first American set foot on the Moon more than 50 years ago. @fayeflam explains why, despite the leaps in technology, it's been so hard to do it again. (via @opinion) https://t.co/WgbyJnZtmL ...

Trump's FTC Chairman Andrew Ferguson is maintaining the agency's focus on tech giants and putting new muscle behind longstanding conservative complaints https://t.co/6GKEKMm2w8 ...

股票简称：甬矽电子 股票代码：688362 甬矽电子（宁波）股份有限公司 Forehope Electronic （Ningbo）Co.,Ltd. （浙江省余姚市中意宁波生态园兴舜路 22 号） 向不特定对象发行可转换公司债券 上市公告书 保荐人（主承销商） （深圳市福田区福田街道益田路 5023 号平安金融中心 B 座第 22-25 层） 二〇二五年七月 第一节 重要声明与提示 甬矽电子（宁波）股份有限公司（以下简称"甬矽电子""发行人""公司" 或"本公司"）全体董事、监事和高级管理人员保证上市公告书的真实性、准确 性、完整性，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并对其 内容的真实性、准确性和完整性承担个别和连带的法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）等有关法律、法规的规定，本公司 董事、高级管理人员已依法履行诚信和勤勉尽责的义务和责任。 中国证券监督管理委员会（以下简称"中国证监会"）、上海证券交易所（以 下简称"上交所"）、其他政府机关对本公司可转换公司债券上市及有关事项的 意见，均不表明对本公司的任何保 ...